
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8881231/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterisation of the Function of a SINE-VNTR-Alu Retrotransposon to Modulate Isoform Expression at the MAPT Locus. Frontiers in Molecular Neuroscience, 2022, 15, 815695.	2.9	7
2	Locus specific reduction of L1 expression in the cortices of individuals with amyotrophic lateral sclerosis. Molecular Brain, 2022, 15, 25.	2.6	2
3	Longitudinal intronic RNA-Seq analysis of Parkinson's disease patients reveals disease-specific nascent transcription. Experimental Biology and Medicine, 2022, 247, 945-957.	2.4	5
4	At the dawn of the transcriptomic medicine. Experimental Biology and Medicine, 2021, 246, 286-292.	2.4	7
5	CRISPR Deletion of a SVA Retrotransposon Demonstrates Function as a cis-Regulatory Element at the TRPV1/TRPV3 Intergenic Region. International Journal of Molecular Sciences, 2021, 22, 1911.	4.1	6
6	Transcript Variants of Genes Involved in Neurodegeneration Are Differentially Regulated by the APOE and MAPT Haplotypes. Genes, 2021, 12, 423.	2.4	7
7	Variable number tandem repeats – Their emerging role in sickness and health. Experimental Biology and Medicine, 2021, 246, 1368-1376.	2.4	11
8	Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain. Current Neuropharmacology, 2021, 19, 665-678.	2.9	13
9	Reference SVA insertion polymorphisms are associated with Parkinson's Disease progression and differential gene expression. Npj Parkinson's Disease, 2021, 7, 44.	5.3	22
10	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
11	Expression Quantitative Trait Loci (eQTLs) Associated with Retrotransposons Demonstrate their Modulatory Effect on the Transcriptome. International Journal of Molecular Sciences, 2021, 22, 6319.	4.1	10
12	TRPA1-Mediated Src Family Kinases Activity Facilitates Cortical Spreading Depression Susceptibility and Trigeminovascular System Sensitization. International Journal of Molecular Sciences, 2021, 22, 12273.	4.1	7
13	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	12.8	44
14	Src family kinases activity is required for transmitting purinergic P2X7 receptor signaling in cortical spreading depression and neuroinflammation. Journal of Headache and Pain, 2021, 22, 146.	6.0	9
15	An Increased Burden of Highly Active Retrotransposition Competent L1s Is Associated with Parkinson's Disease Risk and Progression in the PPMI Cohort. International Journal of Molecular Sciences, 2020, 21, 6562.	4.1	18
16	A SINE-VNTR-Alu in the LRIG2 Promoter Is Associated with Gene Expression at the Locus. International Journal of Molecular Sciences, 2020, 21, 8486.	4.1	6
17	Frequency and methylation status of selected retrotransposition competent L1 loci in amyotrophic lateral sclerosis. Molecular Brain, 2020, 13, 154.	2.6	7
18	Genetic Risk Profiling in Parkinson's Disease and Utilizing Genetics to Gain Insight into Disease-Related Biological Pathways. International Journal of Molecular Sciences, 2020, 21, 7332.	4.1	16

#	Article	IF	CITATIONS
19	Genetic interaction between two VNTRs in the MAOA gene is associated with the nicotine dependence. Experimental Biology and Medicine, 2020, 245, 733-739.	2.4	6
20	Sarcoma Family Kinase-Dependent Pannexin-1 Activation after Cortical Spreading Depression Is Mediated by NR2A-Containing Receptors. International Journal of Molecular Sciences, 2020, 21, 1269.	4.1	14
21	Letter to the editor regarding "TGM6 variants in Parkinson's disease: clinical findings and functional evidence― Journal of Integrative Neuroscience, 2020, 19, 735.	1.7	0
22	Non-coding genetic variation shaping mental health. Current Opinion in Psychology, 2019, 27, 18-24.	4.9	14
23	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
24	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€ s pecific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
25	Mismatched Prenatal and Postnatal Maternal Depressive Symptoms and Child Behaviours: A Sex-Dependent Role for NR3C1 DNA Methylation in the Wirral Child Health and Development Study. Cells, 2019, 8, 943.	4.1	12
26	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
27	Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset. Npj Parkinson's Disease, 2019, 5, 8.	5.3	95
28	Analysis of repetitive element expression in the blood and skin of patients with Parkinson's disease identifies differential expression of satellite elements. Scientific Reports, 2019, 9, 4369.	3.3	12
29	Treating the "E―in "G × E― Trauma-Informed Approaches and Psychological Therapy Interventions in Psychosis. Frontiers in Psychiatry, 2019, 10, 9.	2.6	12
30	The Role of SINE-VNTR-Alu (SVA) Retrotransposons in Shaping the Human Genome. International Journal of Molecular Sciences, 2019, 20, 5977.	4.1	22
31	Retrotransposons in the development and progression of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 284-293.	1.9	29
32	Distinct chromatin structures at the monoamine oxidaseâ€A promoter correlate with alleleâ€specific expression in SHâ€&Y5Y cells. Genes, Brain and Behavior, 2019, 18, e12483.	2.2	3
33	Regulatory characterisation of the schizophrenia-associated CACNA1C proximal promoter and the potential role for the transcription factor EZH2 in schizophrenia aetiology. Schizophrenia Research, 2018, 199, 168-175.	2.0	22
34	Statistical analysis of human microarray data shows that dietary intervention with <i>n</i> -3 fatty acids, flavonoids and resveratrol enriches for immune response and disease pathways. British Journal of Nutrition, 2018, 119, 239-249.	2.3	9
35	Sarcoma family kinase activity is required for cortical spreading depression. Cephalalgia, 2018, 38, 1748-1758.	3.9	9
36	The Regulation of Monoamine Oxidase A Gene Expression by Distinct Variable Number Tandem Repeats. Journal of Molecular Neuroscience, 2018, 64, 459-470.	2.3	24

#	Article	IF	CITATIONS
37	Genetic Interaction Between Two VNTRs in the SLC6A4 Gene Regulates Nicotine Dependence in Vietnamese Men. Frontiers in Pharmacology, 2018, 9, 1398.	3.5	8
38	LRP10 in α-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	10.2	15
39	Neuropeptides-2015, Aberdeen University, Scotland. Neuropeptides, 2017, 64, 1.	2.2	0
40	Novel brain expressed RNA identified at the MIR137 schizophrenia-associated locus. Schizophrenia Research, 2017, 184, 109-115.	2.0	12
41	SVA retrotransposons as potential modulators of neuropeptide gene expression. Neuropeptides, 2017, 64, 3-7.	2.2	26
42	Hemokinin-1 mediates anxiolytic and anti-depressant-like actions in mice. Brain, Behavior, and Immunity, 2017, 59, 219-232.	4.1	17
43	Potential impact of primate-specific SVA retrotransposons during the evolution of human cognitive function. Trends in Evolutionary Biology, 2017, 6, .	0.4	4
44	NR2A contributes to genesis and propagation of cortical spreading depression in rats. Scientific Reports, 2016, 6, 23576.	3.3	15
45	Identification and Potential Regulatory Properties of Evolutionary Conserved Regions (ECRs) at the Schizophrenia-Associated MIR137 Locus. Journal of Molecular Neuroscience, 2016, 60, 239-247.	2.3	3
46	Gender and estrous cycle influences on behavioral and neurochemical alterations in adult rats neonatally administered ketamine. Developmental Neurobiology, 2016, 76, 519-532.	3.0	23
47	Role of capsaicin-sensitive nerves and tachykinins in mast cell tryptase-induced inflammation of murine knees. Inflammation Research, 2016, 65, 725-736.	4.0	23
48	A TOMM40 poly-T variant modulates gene expression and is associated with vocabulary ability and decline in nonpathologic aging. Neurobiology of Aging, 2016, 39, 217.e1-217.e7.	3.1	34
49	NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy. Epilepsy and Behavior, 2016, 54, 117-127.	1.7	19
50	A GWAS SNP for Schizophrenia Is Linked to the Internal MIR137 Promoter and Supports Differential Allele-Specific Expression. Schizophrenia Bulletin, 2016, 42, 1003-1008.	4.3	31
51	Analysis of the effects of depression associated polymorphisms on the activity of the BICC1 promoter in amygdala neurones. Pharmacogenomics Journal, 2016, 16, 366-374.	2.0	14
52	Characterisation of multiple regulatory domains spanning the major transcriptional start site of the FUS gene, a candidate gene for motor neurone disease. Brain Research, 2015, 1595, 1-9.	2.2	4
53	Characterization of a REST-Regulated Internal Promoter in the Schizophrenia Genome-Wide Associated Gene MIR137. Schizophrenia Bulletin, 2015, 41, 698-707.	4.3	37
54	Regulation of <i>SPRY3</i> by X chromosome and PAR2-linked promoters in an autism susceptibility region. Human Molecular Genetics, 2015, 24, 5126-5141.	2.9	16

#	Article	IF	CITATIONS
55	Effects of prenatal and postnatal depression, and maternal stroking, at the glucocorticoid receptor gene. Translational Psychiatry, 2015, 5, e560-e560.	4.8	142
56	Molecular signatures of mood stabilisers highlight the role of the transcription factor REST/NRSF. Journal of Affective Disorders, 2015, 172, 63-73.	4.1	10
57	An Evaluation of a SVA Retrotransposon in the FUS Promoter as a Transcriptional Regulator and Its Association to ALS. PLoS ONE, 2014, 9, e90833.	2.5	32
58	SVA retrotransposons as modulators of gene expression. Mobile Genetic Elements, 2014, 4, e32102.	1.8	23
59	Moodâ€stabilizers differentially affect housekeeping gene expression in human cells. International Journal of Methods in Psychiatric Research, 2014, 23, 279-288.	2.1	14
60	Role of neurokinin 1 receptors in dextran sulfate-induced colitis: studies with gene-deleted mice and the selective receptor antagonist netupitant. Inflammation Research, 2014, 63, 399-409.	4.0	10
61	Characterisation of the potential function of SVA retrotransposons to modulate gene expression patterns. BMC Evolutionary Biology, 2013, 13, 101.	3.2	55
62	Alleleâ€specific expression of the serotonin transporter and its transcription factors following lamotrigine treatment in vitro. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 474-483.	1.7	7
63	Polymorphic variation as a driver of differential neuropeptide gene expression. Neuropeptides, 2013, 47, 395-400.	2.2	8
64	Evidence for interplay between genes and parenting on infant temperament in the first year of life: monoamine oxidase A polymorphism moderates effects of maternal sensitivity on infant anger proneness. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2013, 54, 1308-1317.	5.2	40
65	Mental health and behaviour. Neuropeptides, 2013, 47, 361.	2.2	3
66	Role of Pituitary Adenylate-Cyclase Activating Polypeptide and Tac1 gene derived tachykinins in sensory, motor and vascular functions under normal and neuropathic conditions. Peptides, 2013, 43, 105-112.	2.4	27
67	Evidence for interplay between genes and maternal stress <i>in utero</i> : monoamine oxidase A polymorphism moderates effects of life events during pregnancy on infant negative emotionality at 5 weeks. Genes, Brain and Behavior, 2013, 12, 388-396.	2.2	37
68	Alleleâ€specific transcriptional activity of the variable number of tandem repeats in 5′ region of the <i><scp>DRD4</scp></i> gene is stimulus specific in human neuronal cells. Genes, Brain and Behavior, 2013, 12, 282-287.	2.2	10
69	Role of Tachykinin 1 and 4 Gene-Derived Neuropeptides and the Neurokinin 1 Receptor in Adjuvant-Induced Chronic Arthritis of the Mouse. PLoS ONE, 2013, 8, e61684.	2.5	28
70	CTCF and Sp1 interact with the Murine gammaherpesvirus 68 internal repeat elements. Virus Genes, 2012, 45, 265-273.	1.6	3
71	A Polymorphism Associated with Depressive Disorders Differentially Regulates Brain Derived Neurotrophic Factor Promoter IV Activity. Biological Psychiatry, 2012, 71, 618-626.	1.3	51
72	Intronic Tandem Repeat in the Serotonin Transporter Gene in Old World Monkeys: a New Transcriptional Regulator?. Journal of Molecular Neuroscience, 2012, 47, 401-407.	2.3	2

#	Article	IF	CITATIONS
73	The <i>SLC6A4</i> VNTR genotype determines transcription factor binding and epigenetic variation of this gene in response to cocaine <i>in vitro</i> . Addiction Biology, 2012, 17, 156-170.	2.6	26
74	Activity-Dependent Neuroprotective Protein Modulates Its Own Gene Expression. Journal of Molecular Neuroscience, 2012, 46, 33-39.	2.3	20
75	Behavioural Genetics of the Serotonin Transporter. Current Topics in Behavioral Neurosciences, 2011, 12, 503-535.	1.7	31
76	Modulation of orbitofrontal response to amphetamine by a functional variant of DAT1 and in vitro confirmation. Molecular Psychiatry, 2011, 16, 124-126.	7.9	8
77	Altered host response to murine gammaherpesvirus 68 infection in mice lacking the tachykinin 1 gene and the receptor for substance P. Neuropeptides, 2011, 45, 49-53.	2.2	4
78	Epigenetical mechanisms of susceptibility to complex human diseases. Russian Journal of Genetics: Applied Research, 2011, 1, 436-447.	0.4	2
79	A long AAAG repeat allele in the 5′ UTR of the ERR-γ gene is correlated with breast cancer predisposition and drives promoter activity in MCF-7 breast cancer cells. Breast Cancer Research and Treatment, 2011, 130, 41-48.	2.5	15
80	Distinct Gene Expression Profiles Directed by the Isoforms of the Transcription Factor Neuron-Restrictive Silencer Factor in Human SK-N-AS Neuroblastoma Cells. Journal of Molecular Neuroscience, 2011, 44, 77-90.	2.3	9
81	Lithium Chloride Regulation of the Substance P Encoding Preprotachykinin A, Tac1 Gene in Rat Hippocampal Primary Cells. Journal of Molecular Neuroscience, 2011, 45, 94-100.	2.3	1
82	An evolutionary conserved region (ECR) in the human dopamine receptor D4 gene supports reporter gene expression in primary cultures derived from the rat cortex. BMC Neuroscience, 2011, 12, 46.	1.9	4
83	Differential Activity by Polymorphic Variants of a Remote Enhancer that Supports Galanin Expression in the Hypothalamus and Amygdala: Implications for Obesity, Depression and Alcoholism. Neuropsychopharmacology, 2011, 36, 2211-2221.	5.4	60
84	The IL1RN Promoter rs4251961 Correlates with IL-1 Receptor Antagonist Concentrations in Human Infection and Is Differentially Regulated by GATA-1. Journal of Immunology, 2011, 186, 2329-2335.	0.8	35
85	Research dissemination and knowledge translation. British Journal of Cardiac Nursing, 2010, 5, 600-604.	0.1	2
86	Involvement of preprotachykinin A gene-encoded peptides and the neurokinin 1 receptor in endotoxin-induced murine airway inflammation. Neuropeptides, 2010, 44, 399-406.	2.2	23
87	Fineâ€mapping reveals novel alternative splicing of the dopamine transporter. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1434-1447.	1.7	18
88	Combinatorial interaction between two human serotonin transporter gene variable number tandem repeats and their regulation by CTCF. Journal of Neurochemistry, 2010, 112, 296-306.	3.9	63
89	Genome-Wide Association Study of Major Recurrent Depression in the U.K. Population. American Journal of Psychiatry, 2010, 167, 949-957.	7.2	221
90	Assessing the Impact of Genetic Variation on Transcriptional Regulation In Vitro. Methods in Molecular Biology, 2010, 628, 195-214.	0.9	1

#	Article	IF	CITATIONS
91	The human neurokinin B gene, TAC3, and its promoter are regulated by Neuron Restrictive Silencing Factor (NRSF) transcription factor family. Neuropeptides, 2009, 43, 333-340.	2.2	21
92	A regulatory domain spanning the repeat sequence RE1 from herpes simplex virus type 1 has cell specific differential functions in trigeminal neurons and fibroblasts. FEBS Letters, 2009, 583, 3335-3338.	2.8	6
93	Nitric Oxide Regulates Activity-Dependent Neuroprotective Protein (ADNP) in the Dentate Gyrus of the Rodent Model of Kainic Acid-Induced Seizure. Journal of Molecular Neuroscience, 2009, 39, 9-21.	2.3	12
94	Investigation of Van Gogh-like 2 mRNA regulation and localisation in response to nociception in the brain of adult common carp (Cyprinus carpio). Neuroscience Letters, 2009, 465, 290-294.	2.1	5
95	Molecular Genetics of Monoamine Transporters: Relevance to Brain Disorders. Neurochemical Research, 2008, 33, 652-667.	3.3	66
96	Additive effect of BDNF and REST polymorphisms is associated with improved general cognitive ability. Genes, Brain and Behavior, 2008, 7, 714-719.	2.2	27
97	Engineering in Genomics [variable number tandem repeats as agents of functional regulation in the genome]. IEEE Engineering in Medicine and Biology Magazine, 2008, 27, 103-108.	0.8	8
98	Behavioural analysis of a nociceptive event in fish: Comparisons between three species demonstrate specific responses. Applied Animal Behaviour Science, 2008, 114, 248-259.	1.9	106
99	Regulation of activity-dependent neuroprotective protein (ADNP) by the NO-cGMP pathway in the hippocampus during kainic acid-induced seizure. Neurobiology of Disease, 2008, 30, 281-292.	4.4	28
100	Mechanical stimulation induces preprotachykinin gene expression in osteoarthritic chondrocytes which is correlated with modulation of the transcription factor neuron restrictive silence factor. Neuropeptides, 2008, 42, 681-686.	2.2	23
101	Novel candidate genes identified in the brain during nociception in common carp (Cyprinus carpio) and rainbow trout (Oncorhynchus mykiss). Neuroscience Letters, 2008, 437, 135-138.	2.1	35
102	Induction of Tachykinin Production in Airway Epithelia in Response to Viral Infection. PLoS ONE, 2008, 3, e1673.	2.5	21
103	Expression of activity-dependent neuroprotective protein in the brain of adult rats. Histology and Histopathology, 2008, 23, 309-17.	0.7	16
104	Differential Regulation of the Serotonin Transporter Gene by Lithium Is Mediated by Transcription Factors, CCCTC Binding Protein and Y-Box Binding Protein 1, through the Polymorphic Intron 2 Variable Number Tandem Repeat. Journal of Neuroscience, 2007, 27, 2793-2801.	3.6	43
105	NO-cGMP mediated galanin expression in NGF-deprived or axotomized sensory neurons. Journal of Neurochemistry, 2007, 100, 790-801.	3.9	20
106	Generation of a transgenic model to address regulation and function of the human neurokinin 1 receptor (NK1R). Neuropeptides, 2007, 41, 195-205.	2.2	2
107	Evidence of Postnatal Neurogenesis in Dorsal Root Ganglion: Role of Nitric Oxide and Neuronal Restrictive Silencer Transcription Factor. Journal of Molecular Neuroscience, 2007, 32, 97-107.	2.3	23
108	Nitric Oxide-NGF Mediated PPTA/SP, ADNP, and VIP Expression in the Peripheral Nervous System. Journal of Molecular Neuroscience, 2007, 33, 268-277.	2.3	14

#	Article	IF	CITATIONS
109	Regulation and role of REST and REST4 variants in modulation of gene expression in in vivo and in vitro in epilepsy models. Neurobiology of Disease, 2006, 24, 41-52.	4.4	79
110	A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4552-4557.	7.1	159
111	Nitric oxide, a biological double-faced janusis this good or bad?. Histology and Histopathology, 2006, 21, 445-58.	0.7	102
112	Substance P and the Tachykinins. , 2006, , 427-461.		0
113	Either nitric oxide or nerve growth factor is required for dorsal root ganglion neurons to survive during embryonic and neonatal development. Developmental Brain Research, 2005, 154, 153-164.	1.7	20
114	A proximal E-box modulates NGF effects on rat PPT-A promoter activity in cultured dorsal root ganglia neurones. Neuropeptides, 2005, 39, 475-483.	2.2	8
115	Glial-mediated neuroprotection: Evidence for the protective role of the NO-cGMP pathway via neuron-glial communication in the peripheral nervous system. Glia, 2005, 49, 197-210.	4.9	62
116	Preferential expression of an AAV-2 construct in NOS-positive interneurons following intrastriatal injection. Molecular Brain Research, 2005, 141, 74-82.	2.3	4
117	YB-1 and CTCF Differentially Regulate the 5-HTT Polymorphic Intron 2 Enhancer Which Predisposes to a Variety of Neurological Disorders. Journal of Neuroscience, 2004, 24, 5966-5973.	3.6	79
118	Regulation of the Cell-specific Calcitonin/Calcitonin Gene-related Peptide Enhancer by USF and the Foxa2 Forkhead Protein. Journal of Biological Chemistry, 2004, 279, 49948-49955.	3.4	20
119	Post-genomic approaches to exploring neuropeptide gene mis-expression in disease. Neuropeptides, 2004, 38, 1-15.	2.2	21
120	Discovering genes: the use of microarrays and laser capture microdissection in pain research. Brain Research Reviews, 2004, 46, 225-233.	9.0	20
121	Allodynia in rats infected with varicella zoster virus—a small animal model for post-herpetic neuralgia. Brain Research Reviews, 2004, 46, 234-242.	9.0	61
122	Detection of Small Cell Lung Cancer by RT-PCR for Neuropeptides, Neuropeptide Receptors, or a Splice Variant of the Neuron Restrictive Silencer Factor. , 2003, 75, 335-352.		8
123	Tachykinin expression in cartilage and function in human articular chondrocyte mechanotransduction. Arthritis and Rheumatism, 2003, 48, 146-156.	6.7	61
124	The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. European Journal of Neuroscience, 2003, 17, 417-420.	2.6	109
125	Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box. Biochemical Journal, 2003, 369, 549-561.	3.7	25
126	A Yeast Artificial Chromosome Containing the Human Preprotachykinin-A Gene Expresses Substance P in Mice and Drives Appropriate Marker-Gene Expression during Early Brain Embryogenesis. Molecular and Cellular Neurosciences, 2002, 19, 72-87.	2.2	18

#	Article	IF	CITATIONS
127	Neuron restrictive silencer factor as a modulator of neuropeptide gene expression. Regulatory Peptides, 2002, 108, 135-141.	1.9	29
128	Real-Time Analysis of Preprotachykinin Promoter Activity in Single Cortical Neurons. Journal of Neurochemistry, 2002, 75, 882-885.	3.9	17
129	Role of Tachykinins in the Host Response to Murine Gammaherpesvirus Infection. Journal of Virology, 2001, 75, 10467-10471.	3.4	15
130	The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. Journal of Neurochemistry, 2001, 79, 1033-1038.	3.9	153
131	A role for Octamer binding protein motifs in the regulation of the proximal preprotachykinin-A promoter. Neuropeptides, 2000, 34, 348-354.	2.2	6
132	Molecular models to analyse preprotachykinin-A expression and function. Neuropeptides, 2000, 34, 292-302.	2.2	16
133	The Human Preprotachykinin-A Gene Promoter Has Been Highly Conserved and Can Drive Human-like Marker Gene Expression in the Adult Mouse CNS. Molecular and Cellular Neurosciences, 2000, 16, 620-630.	2.2	24
134	Herpes virus latency in sensory ganglia — a comparison with endogenous neuronal gene expression. Progress in Neurobiology, 2000, 60, 167-179.	5.7	28
135	A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Research, 2000, 60, 1840-4.	0.9	102
136	A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 15251-15255.	7.1	340
137	Characterization of potential regulatory elements within the rat arginine vasopressin proximal promoter. Neuropeptides, 1999, 33, 81-90.	2.2	28
138	An intronic domain within the rat preprotachykinin-A gene containing a CCCT repetitive motif acts as an enhancer in differentiating embryonic stem cells. Neuroscience Letters, 1999, 263, 141-144.	2.1	9
139	Neuronal-specific and nerve growth factor-inducible expression directed by the preprotachykinin-A promoter delivered by an adeno-associated virus vector. Neuroscience, 1999, 94, 997-1003.	2.3	22
140	An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Letters, 1999, 458, 171-174.	2.8	237
141	Novel cell lines for the analysis of preprotachykinin A gene expression identify a repressor domain 3′ of the major transcriptional start site. Biochemical Journal, 1999, 341, 847.	3.7	8
142	Novel cell lines for the analysis of preprotachykinin A gene expression identify a repressor domain 3′ of the major transcriptional start site. Biochemical Journal, 1999, 341, 847-852.	3.7	11
143	E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer. Biochemical Journal, 1999, 344, 961-970.	3.7	27
144	Neuronal specific and NGF inducible expression directed by the Preprotachykinin-A promoter delivered by an adeno-associated viral vector. Biochemical Society Transactions, 1999, 27, A94-A94.	3.4	0

#	Article	IF	CITATIONS
145	Neuron restrictive silencer factor (NRSF) regulates the substance P encoding preprotachykinin-A gene. Biochemical Society Transactions, 1999, 27, A95-A95.	3.4	0
146	E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer. Biochemical Journal, 1999, 344, 961.	3.7	9
147	Behavioural changes in the rat following infection with varicella-zoster virus. Journal of General Virology, 1999, 80, 2433-2436.	2.9	76
148	Novel cell lines for the analysis of preprotachykinin A gene expression identify a repressor domain 3' of the major transcriptional start site. Biochemical Journal, 1999, 341 (Pt 3), 847-52.	3.7	3
149	E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer. Biochemical Journal, 1999, 344 Pt 3, 961-70.	3.7	6
150	Arginine vasopressin promoter regulation is mediated by a neuron-restrictive silencer element in small cell lung cancer. Cancer Research, 1999, 59, 5123-7.	0.9	28
151	A role for the octamer-binding protein in preprotachykinin-a gene expression. Neuropeptides, 1998, 32, 79-85.	2.2	9
152	Identification of a novel multifunctional structural domain in the herpes simplex virus type 1 genome: implications for virus latency Journal of General Virology, 1998, 79, 2529-2532.	2.9	7
153	19 The role of the Octamer binding proteins and the NF-kB complex in neuropeptide gene expression. Biochemical Society Transactions, 1997, 25, S573-S573.	3.4	4
154	NEURONAL-SPECIFIC GENE EXPRESSION μ THE INTERACTION OF BOTH POSITIVE AND NEGATIVE TRANSCRIPTIONAL REGULATORS. Progress in Neurobiology, 1996, 50, 363-379.	5.7	49
155	Structure of a variable number tandem repeat of the serotonin transporter gene and association with affective disorder. Psychiatric Genetics, 1996, 6, 177-182.	1.1	120
156	Estrogen control of central neurotransmission: Effect on mood, mental state, and memory. Cellular and Molecular Neurobiology, 1996, 16, 325-344.	3.3	385
157	Ku-related antigens are associated with transcriptionally active loci inChironomus polytene chromosomes. Chromosoma, 1996, 105, 150-157.	2.2	7
158	The molecular biology of preprotachykinin-A gene expression. Neuropeptides, 1996, 30, 602-610.	2.2	28
159	An upstream stimulatory factor (USF) binding motif is critical for rat preprotachykinin-A promoter activity in PC12 cells. Biochemical Journal, 1995, 310, 401-406.	3.7	31
160	Multiple protein complexes, including AP2 and Sp1, interact with a specific site within the rat preprotachykinin-A promoter. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1995, 1263, 25-34.	2.4	13
161	Transcriptional control of neuropeptide gene expression in sensory neurons, using the preprotachykinin-A gene as a model. Canadian Journal of Physiology and Pharmacology, 1995, 73, 957-962.	1.4	15
162	Characterisation of a functional E box motif in the proximal rat preprotachykinin-A promoter. Neuroscience Letters, 1995, 191, 185-188.	2.1	24

#	Article	IF	CITATIONS
163	Repression of preprotachykinin-A promoter activity is mediated by a proximal promoter element. Neuroscience, 1995, 65, 837-847.	2.3	40
164	Characterisation of potential regulatory elements within the rat preprotachykinin-A promoter. Neuroscience Letters, 1995, 184, 125-128.	2.1	35
165	Three immediate early gene response elements in the proximal preprotachykinin-A promoter in two functionally distinct domains. Neuroscience, 1995, 66, 921-932.	2.3	31
166	An Activator Element within the Preprotachykinin-A Promoter. Molecular and Cellular Neurosciences, 1994, 5, 165-175.	2.2	34
167	The rat vasoactive intestinal polypeptide cyclic AMP response element regulates gene transcriptional responses differently in neonatal and adult rat sensory neurons. Neuroscience Letters, 1994, 167, 19-23.	2.1	11
168	The rat preprotachykinin-A promoter is regulated in PC12 cells by the synergistic action of multiple stimuli. Neuroscience Letters, 1994, 181, 117-120.	2.1	23
169	The preprotachykinin A promoter interacts with a sequence specific single stranded DNA binding protein. Nucleic Acids Research, 1993, 21, 1637-1641.	14.5	18
170	Evolution of enhancer domains within the preprotachykinin promoter. Biochemical Society Transactions, 1993, 21, 371S-371S.	3.4	2
171	Identification of potential regulatory elements within the rat pre-protachykinin A promoter. Biochemical Society Transactions, 1993, 21, 372S-372S.	3.4	1
172	The preprotachykinin A promoter interacts with a sequence specific single stranded DNA binding protein. Biochemical Society Transactions, 1993, 21, 373S-373S.	3.4	0
173	The Nuclear Autoimmune Antigen Ku IS Also Present on the Cell Surface. Autoimmunity, 1992, 13, 265-267.	2.6	38
174	Identification of a neuronal specific DNA-binding protein within the rat preprotachykinin promoter. Biochemical Society Transactions, 1992, 20, 264S-264S.	3.4	0
175	An NGF-inducible octamer binding protein activity in a C1300 neuroblastoma cell line. Molecular Brain Research, 1992, 15, 174-178.	2.3	4
176	Multiple protein binding sites within the rat preprotachykinin promoter: Demonstration of a site with neuronal specificity that is 3′ of the major transcriptional start. Molecular and Cellular Neurosciences, 1992, 3, 11-16.	2.2	14
177	The Ku complex is modulated in response to viral infection and other cellular changes. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1131, 181-187.	2.4	12
178	Variation in the composition of the AP1 complex in PC12 cells following induction by NGF and TPA. Molecular and Cellular Neurosciences, 1991, 2, 253-258.	2.2	11
179	Autoimmune antigen Ku is enriched on oligonucleotide columns distinct from those containing the octamer binding protein DNA consensus sequence. FEBS Letters, 1991, 286, 225-228.	2.8	21
180	Multiple components are required for sequence recognition of the AP1 site in the gibbon ape leukemia virus enhancer Molecular and Cellular Biology, 1989, 9, 4713-4721.	2.3	19

#	Article	IF	CITATIONS
181	fos/jun and Octamer-binding Protein Interact with a Common Site in a Negative Element of the Human c-myc Gene. Journal of Biological Chemistry, 1989, 264, 8992-8999.	3.4	95
182	Distinct factors bind the AP-1 consensus sites in gibbon ape leukemia virus and simian virus 40 enhancers. Journal of Virology, 1989, 63, 1737-1742.	3.4	51
183	Multiple Components Are Required for Sequence Recognition of the API Site in the Gibbon Ape Leukemia Virus Enhancer. Molecular and Cellular Biology, 1989, 9, 4713-4721.	2.3	10
184	fos/jun and octamer-binding protein interact with a common site in a negative element of the human c-myc gene. Journal of Biological Chemistry, 1989, 264, 8992-9.	3.4	84
185	Binding of a cellular protein to the gibbon ape leukemia virus enhancer Molecular and Cellular Biology, 1987, 7, 2735-2744.	2.3	45
186	Binding of a cellular protein to the gibbon ape leukemia virus enhancer. Molecular and Cellular Biology, 1987, 7, 2735-2744.	2.3	28
187	DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein. Nucleic Acids Research, 1985, 13, 8143-8163.	14.5	256